Xintela AB
XINT | ST
Overview
Corporate Details
- ISIN(s):
- SE0007756903 (+2 more)
- LEI:
- 549300SMDH1EOLCBQU68
- Country:
- Sweden
- Address:
- MEDICON VILLAGE, 223 81 Lund
- Website:
- https://xintela.se/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Xintela AB is a biopharmaceutical company that develops novel treatments in regenerative medicine and targeted oncology. The company's operations are divided into two main areas: stem cell therapies and cancer treatments. Its stem cell division focuses on developing treatments for conditions with high unmet medical needs, such as osteoarthritis and difficult-to-heal leg ulcers. Through its wholly-owned subsidiary, Targinta, the company develops targeted antibody-based therapies for aggressive cancers, including triple-negative breast cancer and glioblastoma. Xintela's therapeutic development is based on its proprietary cell surface marker, integrin α10β1, which serves as a key component of its technology platform for both business areas.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Xintela AB.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| No filings match the current criteria. | ||||
Automate Your Workflow. Get a real-time feed of all Xintela AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Xintela AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
